# KIT

2 EU-approved indications of 1 drug need a KIT result, in 1 tumour type, most of them in gastrointestinal stromal tumour.

## Approved indications by tumour

### Gastrointestinal stromal tumour

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | KIT-positive | Monotherapy | Adjuvant | After resection of Kit (CD117)-positive GIST; Significant risk of relapse; patients who have a low or very low risk of recurrence should not receive adjuvant treatment |
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | KIT-positive | Monotherapy | Advanced | - |

## Label wording

- **Imatinib** (Glivec), Gastrointestinal stromal tumour, advanced: “the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)
- **Imatinib** (Glivec), Gastrointestinal stromal tumour, adjuvant: “the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/kit